



BIOSENSORS
INTERNATIONAL

NEWS RELEASE

**Biosensors' polymer-free drug-eluting stent
technology highlighted during Singapore LIVE 2007**

Singapore, 24 January 2007 – Biosensors International Group, Ltd., (“Biosensors” or the “Company”, Bloomberg: BIG SP), today announced that its polymer-free BioMatrix[®] Freedom[™] drug-eluting stent was presented at a scientific symposium organized in conjunction to the 17th Singapore LIVE (“Sing Live”) convention. Sing Live is an annual convention organized by the Singapore National Heart Centre, and is attended by international cardiologists including leading cardiologists from Asia, Europe and the United States. The convention is being held from 22-24 January 2007 at Singapore’s Suntec Convention Hall.

During the symposium, Biosensors’ next generation drug-eluting stent, BioMatrix Freedom, a state-of-the-art, polymer-free Biolimus A9[®]-eluting stent was presented by Professor Eberhard Grube, Chief of Cardiology and Angiology of the Helios Heart Centre, Siegburg, Germany. BioMatrix Freedom features the Company’s newest drug-eluting stent advancements whereby its proprietary Biolimus A9 drug is directly coated onto the stent’s modified outer surface (abluminal surface). This eliminates the need to use polymers to modulate drug release. In October 2006, Prof. Grube implanted the first BioMatrix Freedom stent during the 18th Transcatheter Cardiovascular Therapeutics scientific symposium held in Washington D.C., U.S.A.

Prof. Grube commented: “Given the challenges faced by current generation drug-eluting stents, biodegradable polymers and now polymer-free drug-eluting stents are certainly heading in the right direction. I feel confident that Biosensors is embarking on the right developments that can better address the needs of the interventional cardiology market.”

Mr. Yoh-Chie Lu, Chairman and CEO of Biosensors commented: "Our current focus is firmly on gaining regulatory clearance to market BioMatrix in Europe and to begin, as soon as possible, our multi-centre clinical trial for that product in the U.S. These innovations underlie our long-term commitment towards providing better alternatives for the treatment of coronary artery disease. We are pleased that while the technology of biodegradable polymer drug-eluting stents is now gaining wider attention, we have pushed ahead and introduced our novel polymer-free drug-eluting stent which we believe can be even more attractive as a solution to the current challenges faced by cardiologists.”

Other highlights of Biosensors during the first two days of Sing Live included two live implantations involving the use of BioMatrix drug-eluting stents by Prof. Grube and Prof. Koh Tian Hai, Director of the Singapore National Heart Centre on the first and second days respectively. These procedures were transmitted “live” via satellite to the convention centre which were witnessed by participating cardiologists. BioMatrix features a new drug-eluting stent platform, a biodegradable polymer, and the anti-restenotic drug Biolimus A9[®] – all proprietary developments of Biosensors.

##End of Release##

Media Contact

Biosensors International Group

Ms Tina Lim, Executive, Corporate Communications

Tel : (65) 6213 5712

Email : media@biosensors.com

Media Relations / Investor Relations Firm

United States

Allen & Caron Inc.

Mr. Matt Clawson

Executive Vice President, Investor Relations

Tel: (1) 949 474 4300

Email: matt@allencaron.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary anti-restenotic drug. It is pursuing three separate drug-eluting stent programs, *BioMatrix*[®], *Axxion*[™], and *BioMatrix*[®] *Freedom*[™], a polymer-free drug-eluting stent, and has licensed aspects of its drug-eluting stent technology to four companies.

Forward Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.